Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved in multiple tumor-derived cell lines expressing wild-type p53, but many have a reduced ability to undergo p53-dependent apoptosis. Gene array analysis revealed attenuated expression of multiple apoptosis-related genes. Cancer cells with mdm2 gene amplification were most sensitive to nutlin-3 in vitro and in vivo, suggesting that MDM2 overexpression may be the only abnormality in the p53 pathway of these cells. Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53-MDM2 interaction.

[1]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[2]  D. Green,et al.  Transcription, apoptosis and p53: catch-22. , 2005, Trends in genetics : TIG.

[3]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[4]  C. Prives,et al.  P53 and Prognosis New Insights and Further Complexity , 2005, Cell.

[5]  Hong Yang,et al.  Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis*♦ , 2004, Journal of Biological Chemistry.

[6]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[7]  L. Vassilev,et al.  Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. , 2003, Molecular cancer therapeutics.

[8]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[9]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[10]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[11]  D. Steensma,et al.  Flow cytometric methods for detection and quantification of apoptosis. , 2003, Methods in molecular medicine.

[12]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[13]  Gideon Rechavi,et al.  DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1 , 2001, Oncogene.

[14]  G. Getz,et al.  DNA microarrays identification of primary and secondary target genes regulated by p53 , 2001, Oncogene.

[15]  F. Zunino,et al.  Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. , 2001, Current medicinal chemistry.

[16]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[17]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[18]  M. Herlyn,et al.  Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[20]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[21]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[22]  Margaret Ashcroft,et al.  Regulation of p53 stability , 1999, Oncogene.

[23]  S B Kaye,et al.  Retinoids: present role and future potential , 1999, British Journal of Cancer.

[24]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[25]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[26]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[27]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[28]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[29]  P. Meltzer,et al.  Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas , 1996, Genes, chromosomes & cancer.

[30]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[31]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[32]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[33]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[34]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[35]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.